Report Content
- Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
- Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
- Executive Summary
- Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter's Five Force Analysis
- Vulvodynia Treatment Market, By Distribution Channel
5.1 Introduction
5.2 Hospital Pharmacies
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Retail Pharmacies
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Drug Store
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Online Pharmacies
5.5.1 Market Overview
5.5.2 Market Size and Forecast
- Vulvodynia Treatment Market, By Drug Class
6.1 Introduction
6.2 Local Anesthetic
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Anticonvulsant
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Tricyclic Antidepressant
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Hormones
6.5.1 Market Overview
6.5.2 Market Size and Forecast
6.6 Serotonin-norepinephrine Reuptake Inhibitors (SNRI)
6.6.1 Market Overview
6.6.2 Market Size and Forecast
6.7 Nerve Block
6.7.1 Market Overview
6.7.2 Market Size and Forecast
6.8 Others
6.8.1 Market Overview
6.8.2 Market Size and Forecast
- Vulvodynia Treatment Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Market, By Distribution Channel
7.2.2 North America Market, By Drug Class
7.3 Europe
7.3.1 Europe Market, By Distribution Channel
7.3.2 Europe Market, By Drug Class
7.4 Asia-Pacific
7.4.1 Asia-Pacific Market, By Distribution Channel
7.4.2 Asia-Pacific Market, By Drug Class
7.5 Rest of the World
7.5.1 Rest of the World Market, By Distribution Channel
7.5.2 Rest of the World Market, By Drug Class
- Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
- Company Profiles
9.1 GlaxoSmithKline plc.
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 AstraZeneca Plc.
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Eli Lilly and Company
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Merck & Co., Inc.
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 Pfizer Inc.
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
9.6 Johnson & Johnson Services, Inc.
9.6.1 Company Overview
9.6.2 Product/Service Landscape
9.6.3 Financial Overview
9.6.4 Recent Developments
9.7 Allergan plc.
9.7.1 Company Overview
9.7.2 Product/Service Landscape
9.7.3 Financial Overview
9.7.4 Recent Developments
9.8 Depomed Inc.
9.8.1 Company Overview
9.8.2 Product/Service Landscape
9.8.3 Financial Overview
9.8.4 Recent Developments
9.9 Par pharmaceutical
9.9.1 Company Overview
9.9.2 Product/Service Landscape
9.9.3 Financial Overview
9.9.4 Recent Developments
9.10 Vertical pharmaceutical
9.10.1 Company Overview
9.10.2 Product/Service Landscape
9.10.3 Financial Overview
9.10.4 Recent Developments